Global Antifungal Drugs Market Report and Forecast 2023-2031
Global Antifungal Drugs Market Outlook
The global antifungal drugs market value was USD 14.8 billion in 2022, driven by the increasing prevalence of fungal infections across the globe. The global antifungal drugs market share is anticipated to grow at a CAGR of 3.7% during the forecast period of 2023-2031 to achieve a value of USD 20.6 billion by 2031.
Antifungal Drugs Market: Introduction
Antifungal drugs are medications used to treat fungal infections, which can affect various parts of the body, including the skin, nails, mouth, lungs, and other organs. These infections can be caused by a wide range of fungi, including Candida, Aspergillus, and Cryptococcus species. Antifungal drugs work by inhibiting the growth of fungi or killing them outright. They are available in various forms, such as oral tablets, creams, ointments, and intravenous injections.
Antifungal Drugs Market Scenario
The global market for antifungal drugs has witnessed significant growth in recent years, driven by factors such as the increasing prevalence of fungal infections, the growing geriatric population, and advancements in antifungal drug development.
North America: The largest market for antifungal drugs, driven by factors such as the advanced healthcare infrastructure, high prevalence of fungal infections, and significant investments in antifungal drug research.
Europe: The second-largest market, with increasing demand for antifungal drugs due to a growing aging population, a supportive regulatory framework, and an expanding pharmaceutical sector.
Asia Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of fungal infections, and growing investments in healthcare infrastructure and pharmaceutical research.
Antifungal Drugs Market Segmentation
Market Breakup by Drug Class
- Azoles
- Voriconazole
- Posaconazole
- Isavuconazole
- Others
- Echinocandins
- Caspofungin
- Micafungin
- Others
- Polyenes
- Amphotericin B
- Others
- Allylamines
- Terbinafine
- Others
- Others
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Mucormysosis
- Others
- Oral
- Cream and Ointments
- Powders
- Injection
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Others
North America
- United States of America
- Canada
- United Kingdom
- Germany
- France
- Italy
- Others
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Brazil
- Argentina
- Mexico
- Others
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the Antifungal Drugs Market
Increasing prevalence of fungal infections: The rising incidence of fungal infections, particularly among immunocompromised individuals, such as patients undergoing chemotherapy or organ transplant recipients, has led to a growing demand for antifungal drugs, driving market growth.
Growing geriatric population: The aging population is more susceptible to fungal infections due to their weakened immune systems, further fuelling the demand for antifungal medications.
Advancements in antifungal drug development: The development of new antifungal drugs with improved efficacy and safety profiles has contributed to market growth. Additionally, the emergence of drug resistance among certain fungal species has spurred research into new antifungal therapies.
Competitor Landscape of the Antifungal Drugs Market
The report gives an in-depth analysis of the key players involved in the antifungal drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Abbott Laboratories
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer Inc.
- BAYER AG
- SANOFI
- MERCK & CO., INC.
- ASTELLAS PHARMA, INC.
- SCYNEXIS INC.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Fungal Disease Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Fungal Disease Epidemiology Analysis
- 5.1 Epidemiology Overview (2016-2031)
- 5.2 North America Fungal Disease Epidemiology (2016-2031)
- 5.3 Europe Fungal Disease Epidemiology (2016-2031)
- 5.4 Asia-Pacific Fungal Disease Epidemiology (2016-2031)
- 5.5 Latin America Fungal Disease Epidemiology (2016-2031)
- 5.6 Middle East & Africa Fungal Disease Epidemiology (2016-2031)
- 6 Global Antifungal Drugs Market Overview
- 6.1 Global Antifungal Drugs Market Historical Value (2016-2022)
- 6.2 Global Antifungal Drugs Market Forecast Value (2023-2031)
- 7 Global Antifungal Drugs Market Landscape
- 7.1 Global Antifungal Drugs Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Global Antifungal Drugs Product Landscape
- 7.2.1 Analysis by Drug Type
- 7.2.2 Analysis by Indication
- 7.2.3 Analysis by Distribution Channel
- 8 Antifungal Drugs Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Global Antifungal Drugs Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Global Antifungal Drugs Market Segmentation
- 11.1 Global Antifungal Drugs Market by Drug Class
- 11.1.1 Market Overview
- 11.1.2 Azoles
- 11.1.2.1 Voriconazole
- 11.1.2.2 Posaconazole
- 11.1.2.3 Isavuconazole
- 11.1.2.4 Others
- 11.1.3 Echinocandins
- 11.1.3.1 Caspofungin
- 11.1.3.2 Micafungin
- 11.1.3.3 Others
- 11.1.4 Polyenes
- 11.1.4.1 Amphotericin B
- 11.1.4.2 Others
- 11.1.5 Allylamines
- 11.1.5.1 Terbinafine
- 11.1.5.2 Others
- 11.1.6 Others
- 11.2 Global Antifungal Drugs Market by Indication
- 11.2.1 Market Overview
- 11.2.2 Dermatophytosis
- 11.2.3 Aspergillosis
- 11.2.4 Candidiasis
- 11.2.5 Mucormysosis
- 11.2.6 Others
- 11.3 Global Antifungal Drugs Market by Dosage Form
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Cream & Ointments
- 11.3.4 Powders
- 11.3.5 Injection
- 11.3.6 Others
- 11.4 Global Antifungal Drugs Market by Distribution Channel
- 11.4.1 Market Overview
- 11.4.2 Hospital Pharmacy
- 11.4.3 Retail Pharmacy
- 11.4.4 Others
- 11.5 Global Antifungal Drugs Market by Region
- 11.5.1 Market Overview
- 11.5.2 North America
- 11.5.3 Europe
- 11.5.4 Asia Pacific
- 11.5.5 Latin America
- 11.5.6 Middle East and Africa
- 12 North America Antifungal Drugs Market
- 12.1 Market Share by Country
- 12.2 United States of America
- 12.3 Canada
- 13 Europe Antifungal Drugs Market
- 13.1 Market Share by Country
- 13.2 United Kingdom
- 13.3 Germany
- 13.4 France
- 13.5 Italy
- 13.6 Others
- 14 Asia Pacific Antifungal Drugs Market
- 14.1 Market Share by Country
- 14.2 China
- 14.3 Japan
- 14.4 India
- 14.5 ASEAN
- 14.6 Australia
- 14.7 Others
- 15 Latin America Antifungal Drugs Market
- 15.1 Market Share by Country
- 15.2 Brazil
- 15.3 Argentina
- 15.4 Mexico
- 15.5 Others
- 16 Middle East and Africa Antifungal Drugs Market
- 16.1 Market Share by Country
- 16.2 Saudi Arabia
- 16.3 United Arab Emirates
- 16.4 Nigeria
- 16.5 South Africa
- 16.6 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Regulatory Framework
- 22.1 Regulatory Overview
- 22.1.1 US FDA
- 22.1.2 EU EMA
- 22.1.3 INDIA CDSCO
- 22.1.4 JAPAN PMDA
- 22.1.5 Others
- 23 Supplier Landscape
- 23.1 Abbott Laboratories
- 23.1.1 Financial Analysis
- 23.1.2 Product Portfolio
- 23.1.3 Demographic Reach and Achievements
- 23.1.4 Mergers and Acquisitions
- 23.1.5 Certifications
- 23.2 GlaxoSmithKline PLC
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Novartis AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Pfizer Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 BAYER AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 SANOFI
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 MERCK & CO., INC.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 ASTELLAS PHARMA, INC.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 SCYNEXIS INC.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 24 Global Antifungal Drugs Market- Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
- 26.1 Very Small Companies
- 26.2 Small Companies
- 26.3 Mid-Sized Companies
- 26.4 Large Companies
- 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
- 27.1 Government Funded
- 27.2 Private Insurance
- 27.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook